Last reviewed · How we verify
NCT07352436
Gut Microbiota and Serum Metabolites as Predictors of Glycemic Variability and Outcomes in Diabetic Kidney Disease
trial in Diabetic Kidney Disease in 270 participants. Not yet recruiting.
30 December 2026
Quick facts
| Lead sponsor | Eighth Affiliated Hospital, Sun Yat-sen University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 270 |
| Start date | 1 February 2026 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 July 2029 |
Conditions studied
- Diabetic Kidney Disease — all drugs for Diabetic Kidney Disease →
Sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Who can join
Adults 18 to 65, any sex, with Diabetic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetic kidney disease (DKD) is one of the main complications of diabetes and a leading cause of end-stage kidney disease. Blood glucose variability is closely associated with disease progression in individuals with DKD. Recent evidence suggests that gut bacteria and their circulating metabolites may play important roles in regulating blood glucose variability and clinical outcomes. However, it remains unclear whether gut bacteria and blood metabolites influence DKD progression through effects on blood glucose variability. This study aims to (1) characterize gut bacteria and blood metabolites in individuals with DKD at different stages and levels of disease severity, and evaluate their value in predicting adverse outcomes; (2) assess the relationships among gut bacteria, blood metabolites, and blood glucose variability; and (3) determine whether gut bacteria and blood metabolites affect clinical outcomes by modulating blood glucose variability. A total of 270 individuals with DKD will be enrolled in a prospective observational cohort. The investigators will conduct continuous glucose monitoring and collect stool and blood samples for advanced analyses of gut microbiota and blood metabolites. The objective is to clarify how gut bacteria and circulating metabolites relate to blood glucose variability and disease prognosis, and to develop tools to identify high-risk individuals at an early stage. Ultimately, the findings may provide new insights and strategies to improve clinical care and quality of life for individuals with DKD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07352436
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Kidney Disease
Currently open trials in the same condition.
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT06666283 — A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients · Phase 1 · recruiting
- NCT07338435 — "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)" · NA · active not recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06532682 — Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes · Phase 4 · active not recruiting
Other Eighth Affiliated Hospital, Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07356674 — Hemi-tibial Plateau Osteotomy Combined With Arthroscopic Repair for Medial Meniscus Posterior Root Tears in Varus Knees · NA · not yet recruiting
- NCT07377864 — Clinical Characteristics and Immune Escape Mechanism of Nontuberculous Mycobacterial Lung Disease in South China · not yet recruiting
- NCT07037849 — The Effects of the Control Strategies of Wearable Lower Limb Rehabilitation Robots · NA · recruiting
- NCT06734260 — Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection · Phase 3 · recruiting
- NCT03075137 — Effect of External Counter Pulsation on Ischemic Stroke · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07352436 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eighth Affiliated Hospital, Sun Yat-sen University
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07352436.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing